第一期试验将在三个月后投资人不知道这个疫苗如何盈利，不过今天的股票却飞涨了16% The biotech company Moderna's effort to develop a vaccine for the novel coronavirus that has sickened more than 30,000 people world-wide is proceeding with "no glitches so far," an official with the National Institutes of Health said at a news conference on Friday afternoon.
Shares of Moderna (ticker: MRNA) shot up more than 10% in the minutes after the statement, though news did not change the timeline that the official, National Institute of Allergy and Infectious Disease director Anthony Fauci , had previously laid out for the vaccine to be ready for testing in humans.
"I'm happy to tell you that there have been no glitches so far," Fauci said Friday afternoon at a press briefing by the president's Coronavirus Task Force . Two weeks ago, on Jan. 21 , Fauci said that it would take around three months for a Moderna vaccine for the virus to enter a first-in-human Phase 1 study. Now, the forecast remains the same.
"We will be in people in a Phase 1 trial within the next 2.5 months," Fauci said.
Moderna is designing the vaccine using its own messenger RNA-based technology. The NIAID has signed on to test the drug. A nongovernmental group called the Coalition for Epidemic Preparedness Innovations is providing funding.
It's not clear how the vaccine could earn money for Moderna . "I don't know today what the revenue model is," the company's chief medical officer, Tal Zaks , told Barron's on Dec. 29 . "In the context of a pandemic, obviously it doesn't fit the normal ways of doing business."
The biotech company Moderna's effort to develop a vaccine for the novel coronavirus that has sickened more than 30,000 people world-wide is proceeding with "no glitches so far," an official with the National Institutes of Health said at a news conference on Friday afternoon.
Shares of Moderna (ticker: MRNA) shot up more than 10% in the minutes after the statement, though news did not change the timeline that the official, National Institute of Allergy and Infectious Disease director Anthony Fauci , had previously laid out for the vaccine to be ready for testing in humans.
"I'm happy to tell you that there have been no glitches so far," Fauci said Friday afternoon at a press briefing by the president's Coronavirus Task Force . Two weeks ago, on Jan. 21 , Fauci said that it would take around three months for a Moderna vaccine for the virus to enter a first-in-human Phase 1 study. Now, the forecast remains the same.
"We will be in people in a Phase 1 trial within the next 2.5 months," Fauci said.
Moderna is designing the vaccine using its own messenger RNA-based technology. The NIAID has signed on to test the drug. A nongovernmental group called the Coalition for Epidemic Preparedness Innovations is providing funding.
It's not clear how the vaccine could earn money for Moderna . "I don't know today what the revenue model is," the company's chief medical officer, Tal Zaks , told Barron's on Dec. 29 . "In the context of a pandemic, obviously it doesn't fit the normal ways of doing business."